Scholarlink

Summary <p>This multicenter study focuses on the latest (2020-2024) trends in candidemia in 155 Italian ICUs, stressing its frequency and lethality, with a shift toward non-<i>albicans</i>, fluconazole-resistant species, namely <i>C. parapsilosis</i>. In this study, resistance to fluconazole prolonged ICU stays without increasing mortality, while non-catheter-related episodes had a more severe prognosis.</p> Rationale <p>Candidemia is the leading fungal bloodstream infection (BSI) in the ICU and carries high mortality. After the COVID-19 pandemic, non-<i>albicans</i>, fluconazole-resistant species increased in Europe, yet contemporary ICU-acquired data are scarce. The primary outcome of this study was to evaluate the incidence of ICU-acquired candidemia per 1,000 “at risk” ICU admissions (ICU length of stay [LOS] ≥ 48&#xa0;h). Secondary analyses compared ICU-acquired candidemia with ICU-acquired bacterial BSI and assessed species distribution, fluconazole susceptibility, and outcomes by fluconazole resistance and by source of infection.</p> Methods <p>Data were drawn from the PROSAFE network, a prospective multicentric observational project conducted across 192 Italian ICUs (2014–2023).</p> Results <p>Among 179,590 ICU admissions, 95,662 were at risk. ICU-acquired candidemia occurred in 373 patients (3.9‰ of at-risk admissions). Compared with ICU-acquired bacterial BSI, candidemia patients had longer intra-ICU and hospital LOS (32 vs 24 days and 44 vs 36&#xa0;days, respectively; <i>p</i> &lt; 0.001) and higher mortality (intra-ICU 41.3% vs 28.7%; intra-hospital 50.3% vs 34.1%; <i>p</i> &lt; 0.001). <i>Candida albicans</i> was isolated in 47.2% of episodes, followed by <i>Candida parapsilosis at</i> 33.0%; the latter is often fluconazole-resistant (53.7%). Mortality did not increase in fluconazole-resistant episodes, but ICU LOS did (36 vs 31&#xa0;days; <i>p</i> = 0.016). Non-catheter-related infections (197/373, 52.8%) had higher intra-hospital mortality rates (57.0% vs 42.9%; <i>p</i> = 0.007).</p> Conclusions <p>ICU-acquired candidemia in Italy remains frequent and lethal, with a worrisome shift in epidemiology and resistance; the latter prolongs ICU stay without increasing mortality. Non-catheter-related episodes had a poorer prognosis. Findings support enhanced surveillance, catheter care, and earlier antifungal therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epidemiology, resistance patterns, and outcomes of candidemia acquired in Italian intensive care units: insights from the GIVITI network (2020–2024)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月8日

查看全文
  • Giovanni Scaglione,
  • Marta Colaneri,
  • Martina Offer,
  • Giorgia Montrucchio,
  • Camilla Genovese,
  • Bruno Viaggi,
  • Francesca Dore,
  • Giovanni Tricella,
  • Lidia Dalfino,
  • Gianpaola Monti,
  • Andrea Gori,
  • Emanuele Palomba,
  • Stefano Finazzi,
  • Giorgia Montrucchio,
  • Fulvio Agostini,
  • Antonello di Paolo,
  • Angelo Pan,
  • Gian Maria Rossolini,
  • Emanuele Russo,
  • Daniela Silengo,
  • Costanza Vicentini,
  • Carla Maria Zotti,
  • Stefano Finazzi,
  • Emanuele Palomba

摘要

Summary

This multicenter study focuses on the latest (2020-2024) trends in candidemia in 155 Italian ICUs, stressing its frequency and lethality, with a shift toward non-albicans, fluconazole-resistant species, namely C. parapsilosis. In this study, resistance to fluconazole prolonged ICU stays without increasing mortality, while non-catheter-related episodes had a more severe prognosis.

Rationale

Candidemia is the leading fungal bloodstream infection (BSI) in the ICU and carries high mortality. After the COVID-19 pandemic, non-albicans, fluconazole-resistant species increased in Europe, yet contemporary ICU-acquired data are scarce. The primary outcome of this study was to evaluate the incidence of ICU-acquired candidemia per 1,000 “at risk” ICU admissions (ICU length of stay [LOS] ≥ 48 h). Secondary analyses compared ICU-acquired candidemia with ICU-acquired bacterial BSI and assessed species distribution, fluconazole susceptibility, and outcomes by fluconazole resistance and by source of infection.

Methods

Data were drawn from the PROSAFE network, a prospective multicentric observational project conducted across 192 Italian ICUs (2014–2023).

Results

Among 179,590 ICU admissions, 95,662 were at risk. ICU-acquired candidemia occurred in 373 patients (3.9‰ of at-risk admissions). Compared with ICU-acquired bacterial BSI, candidemia patients had longer intra-ICU and hospital LOS (32 vs 24 days and 44 vs 36 days, respectively; p < 0.001) and higher mortality (intra-ICU 41.3% vs 28.7%; intra-hospital 50.3% vs 34.1%; p < 0.001). Candida albicans was isolated in 47.2% of episodes, followed by Candida parapsilosis at 33.0%; the latter is often fluconazole-resistant (53.7%). Mortality did not increase in fluconazole-resistant episodes, but ICU LOS did (36 vs 31 days; p = 0.016). Non-catheter-related infections (197/373, 52.8%) had higher intra-hospital mortality rates (57.0% vs 42.9%; p = 0.007).

Conclusions

ICU-acquired candidemia in Italy remains frequent and lethal, with a worrisome shift in epidemiology and resistance; the latter prolongs ICU stay without increasing mortality. Non-catheter-related episodes had a poorer prognosis. Findings support enhanced surveillance, catheter care, and earlier antifungal therapy.